Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2005
10/11/2005CA2341949C Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses
10/06/2005WO2005093083A1 Method of disease prediction and method of using the same
10/06/2005WO2005093068A1 Novel protein and promoter
10/06/2005WO2005093064A1 Novel galectin 9 modification protein and use thereof
10/06/2005WO2005092382A1 Therapeutic agent for diabetes containing insulin resistance improving agent
10/06/2005WO2005092367A1 Composition for promoting adiponectin secretion
10/06/2005WO2005092363A1 Preventive/remedy for diabetic complications using oligopeptide
10/06/2005WO2005092349A1 Insulin resistance improving agent
10/06/2005WO2005092328A1 Fxr activation compound
10/06/2005WO2005092322A1 Natural compound causing rar activation
10/06/2005WO2005092320A1 Cytoprotective composition
10/06/2005WO2005092122A1 Composition comprising yucca extract, quillaia extract and lactic acid bacterium and food and drink containing the composition
10/06/2005WO2005072066A3 Preventive or therapeutic agent for diabetic maculopathy
10/06/2005WO2004072031A8 Phenylacetamides and their use as glucokinase modulators
10/06/2005WO2004041193A3 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
10/06/2005US20050222424 Phenyloxyalkanonic acid derivatives as hppar activators
10/06/2005US20050222423 Carboxylic acid derivative
10/06/2005US20050222420 Chain oligolactic acid thioester
10/06/2005US20050222418 Novel tyloindicines and related processes, pharmaceutical compositions and methods
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222259 Methods of activating PPAR-alpha nuclear receptors in mammals
10/06/2005US20050222253 Anti-cancer nitro- and thia-fatty acids
10/06/2005US20050222243 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/06/2005US20050222237 Inhibitors of glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase; for treatment and prevention of diabetes and Alzheimer's disease
10/06/2005US20050222221 Cell differentiation, regeneration of pancreas epithelial cells to insulin producing beta cells; administering a dipeptidyl-peptidase activators
10/06/2005US20050222220 GSK-3 inhibitors
10/06/2005US20050222204 Therapy for obesity; using secondary amino compound; antidiabetic agents; irritable bowel syndrome; nausea, antidepressants, drug abuse
10/06/2005US20050222201 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2)
10/06/2005US20050222194 3-[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-quinolin-2(1H)-ones or 5--[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-pyrrolo[3,2,1-IJ]quinolin-4(4H)-ones; type E antagonists; analgesics, antipyretics, antiinflammatory agents; side effect reduction
10/06/2005US20050222179 Adenosine receptor antagonists and methods of making and using the same
10/06/2005US20050222172 Active ingredient in treating neurodegenerative disease, Alzheimer's disease caused by abnormal enzyme activity
10/06/2005US20050222161 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
10/06/2005US20050222160 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone, used for inhibiting proliferation of lymphocytes in a host, and for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, arthritis, multiple sclerosis, diabetes
10/06/2005US20050222147 Process for the preparation of morpholine derivatives and intermediates therefore
10/06/2005US20050222140 Improved DP-IV inhibitors increase the steady state concentrations of GLP-1 and GIP, resulting in improved glucose tolerance
10/06/2005US20050222138 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
10/06/2005US20050222137 Combination of organic compounds
10/06/2005US20050222125 For therapy of depression, anxiety and body weight disorders
10/06/2005US20050222124 Benzenesulfonamide derivatives as antipsychotic agents
10/06/2005US20050222120 Peptides derivatives comprising thiazepine group for the treatment of hyperlipidermic conditions
10/06/2005US20050222099 Pregnane steroids for use in the treatment of cns disorders
10/06/2005US20050222084 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
10/06/2005US20050222079 Preparation containing folic acid, vitamin b6, and vitamin b12, and use thereof
10/06/2005US20050222078 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
10/06/2005US20050222041 oligopeptides capable of stimulating neural cell adhesion molecule (NCAM) signalling and/or interfering with cell adhesion, used for treatment of nervous system disorders
10/06/2005US20050222025 Method of inhibiting fibrosis with a somatostatin agonist
10/06/2005US20050222010 Composition for treating or preventing hyperuricemia
10/06/2005US20050221420 Nogo receptor homologues and their use
10/06/2005US20050221368 Methods for identifying RNA binding compounds
10/06/2005US20050220900 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta
10/06/2005US20050220884 Free-flowing, powdery composition containing alpha-liponic acid (derivates)
10/06/2005US20050220857 Physiologically compatible, phospholipid-containing, stable and hard matrix
10/06/2005US20050220845 Foods and drinks having health benefits and method for adding health benefits to foods and drinks
10/06/2005US20050220804 Increasing an immune response in an animal, comprising administering a compound (such as a carbohydrate, an antibiotic, a sugar, a protein, or an antibody) that binds a C-type lectin (but not the DEC-205 receptor) on the surface of a dendritic cell
10/06/2005US20050220722 Method of decreasing fasting sugars and weight gains in diabetic patients
10/06/2005DE102004012676A1 New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis)
10/06/2005CA2627940A1 Process for the production of atorvastatin calcium in amorphous form
10/06/2005CA2561696A1 Novel modified galectin 9 proteins and use thereof
10/06/2005CA2560928A1 Therapeutic agent for diabetes containing insulin resistance improving agent
10/06/2005CA2560927A1 Insulin resistance-improving agent
10/06/2005CA2560920A1 Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia
10/06/2005CA2559461A1 Use of metformin and orlistat for the treatment or prevention of obesity
10/06/2005CA2557782A1 Glycol linked fgf-21 compounds
10/05/2005EP1582586A1 Apoptosis-associated protein and use thereof
10/05/2005EP1582521A1 Fused furan compound
10/05/2005EP1582211A1 Jnk inhibitor
10/05/2005EP1582102A1 Foods and drinks having health benefits
10/05/2005EP1581616A2 Novel proteins and nucleic acids encoding same
10/05/2005EP1581614A2 Nucleotide sequences for gene regulation and methods of use thereof
10/05/2005EP1581543A2 Methods of producing c-aryl glucoside sglt2 inhibitors
10/05/2005EP1581521A1 Fused heterocyclic derivatives as ppar modulators
10/05/2005EP1581515A1 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
10/05/2005EP1581505A1 Pyridazinone derivatives as gsk-3beta inhibitors
10/05/2005EP1581491A1 Indole derivatives as ppar modulators
10/05/2005EP1581476A2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors
10/05/2005EP1581240A1 Cholesterol-reducing agent containing an n-3 fatty acid
10/05/2005EP1581221A2 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
10/05/2005EP1581216A1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
10/05/2005EP1581215A1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
10/05/2005EP1581095A2 Therapeutic methods for reducing fat deposition and treating associated conditions
10/05/2005EP1516866A9 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
10/05/2005EP1325008B1 Piperazine derivatives
10/05/2005EP1294393B1 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment and diagnosis of athersclerosis
10/05/2005EP1233950B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
10/05/2005EP1133279B1 Method of producing vitamin powders
10/05/2005EP1124571B1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia
10/05/2005EP1001783B1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
10/05/2005CN1678734A Differentiation modulating agents and uses therefor
10/05/2005CN1678628A Stress proteins and peptides and methods of use thereof
10/05/2005CN1678626A Estrieno[3, 2-b]/[3, 4-c]pyrrole derivatives useful as modulators of the estrogen receptors
10/05/2005CN1678608A New neuropeptide y y5 receptor antagonists
10/05/2005CN1678597A Novel quaternary ammonium compounds
10/05/2005CN1678594A Morpholin-acetamide derivatives for the treatment of inflammatory diseases
10/05/2005CN1678589A Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them
10/05/2005CN1678586A 取代的喹啉ccr5受体拮抗剂 Substituted quinoline ccr5 receptor antagonist
10/05/2005CN1678581A Indolin phenylsulfonamide derivatives
10/05/2005CN1678578A Indoles having anti-diabetic activity
10/05/2005CN1678577A HMG-COA reductase inhibitors
10/05/2005CN1678575A Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
1 ... 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 ... 1298